GDC-6036 是一种具有口服生物利用度,选择性的 KRAS G12C 抑制剂,IC50 为 <0.01 μM。GDC-6036 与 KRAS G12C 的开关 II (SW-II) 口袋共价结合,并将其不可逆地锁定在非活动的 GDP 结合状态。
生物活性
GDC-6036 is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC 50 of <0.01 μM. GDC-6036 covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state.
性状
Solid
IC50 & Target[1][2]
K-Ras(G12C) <0.01 μM (IC50)
体外研究(In Vitro)
GDC-6036 (compound 17a) has an EC50 of 2 nM in K-Ras G12C-alkylation HCC1171 cells has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
GDC-6036 (10-100 mg/kg/day; PO for 7 days) decreases the ratio of free KRAS G12C. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Female C.B-17 SCID (Inbred) mice (20-21 weeks old; 24
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Lingyao Meng, et al. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. Anal Chem. 2022 Sep 20;94(37):12927-12933.[2]. Sushant Malhotra, et al. Fused ring compounds. WO2020097537A2.
溶解度数据
In Vitro: DMSO : 100 mg/mL (160.76 mM; Need ultrasonic)配制储备液